GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » Short Percentage of Float

Infant Bacterial Therapeutics AB (STU:9IB) Short Percentage of Float


View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Infant Bacterial Therapeutics AB's Short Percentage of Float

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Short Percentage of Float falls into.


;
;

Infant Bacterial Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » Short Percentage of Float
Comparable Companies
XSAT:HAMLET B OSTO:DMYD B OSTO:MAGLE OSTO:FLUO OSTO:SYNACT OSTO:SANION OSTO:ONCO OSTO:CANTA OSTO:INIT OSTO:IRLAB A VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
IBT B:Sweden
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Website
https://www.ibtherapeutics.com
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines